Related Experiment Video

Updated: Jul 13, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4

Dawn E Post1, Eric M Sandberg, Michele M Kyle

  • 1Department of Neurosurgery, Winship Cancer Institute, Emory University School of Medicine, 1365C Clifton Road, Atlanta, GA 30322, USA. postd@upstate.ede

Cancer Research
|July 20, 2007
PubMed

Insights

A novel oncolytic adenovirus armed with interleukin-4 (HYPR-Ad-IL4) effectively targets hypoxic tumor cells. This therapy induces tumor regression and a potent antitumor immune response, offering broad therapeutic potential for solid tumors.

Area of Science:

  • Oncolytic virotherapy
  • Cancer immunology
  • Tumor microenvironment

Background:

  • Hypoxic tumor cells resist therapy and express hypoxia-inducible factor-1 (HIF-1).
  • HIF-1 drives metabolic adaptation, angiogenesis, and therapeutic resistance.
  • Novel strategies are needed to target these resistant hypoxic tumor cells.

Purpose of the Study:

  • To develop and evaluate an oncolytic adenovirus (HYPR-Ad-IL4) engineered to target hypoxic/HIF-active tumor cells.
  • To assess the hypoxia-dependent expression of interleukin-4 (IL-4) and its therapeutic efficacy.
  • To investigate the potential of HYPR-Ad-IL4 in inducing antitumor immune responses and tumor regression.

Main Methods:

  • Engineering of HYPR-Ad-IL4 by cloning viral replication and IL-4 genes under a hypoxia-responsive promoter.
  • In vitro assessment of hypoxia-dependent viral replication and cell lysis.
  • In vivo treatment of human tumor xenografts in established models.

Main Results:

  • HYPR-Ad-IL4 demonstrated hypoxia-dependent IL-4 expression, viral replication, and selective lysis of hypoxic cells.
  • Treatment led to rapid, maintained tumor regression comparable to wild-type adenovirus.
  • Tumors exhibited necrosis, fibrosis, viral replication, leukocyte infiltration, and persistent hypoxia.

Conclusions:

  • HYPR-Ad-IL4 is a novel oncolytic adenovirus that selectively targets hypoxic tumor cells.
  • Local delivery of IL-4 via HYPR-Ad-IL4 induces potent antitumor immunity and regression.
  • This therapy holds broad potential for solid tumors characterized by hypoxia or active HIF.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...